Quarterly ResultMay 14, 2026, 04:29 PM
Fennec Pharmaceuticals Q1 Net Income $201K; Sales Up 72.6% to $15.1M
AI Summary
Fennec Pharmaceuticals reported a net income of $201 thousand for the first quarter of 2026, a significant improvement from a net loss of $1,165 thousand in the prior year. This turnaround was driven by a 72.6% increase in PEDMARK product sales, reaching $15.1 million. The company also generated positive cash flow from operating activities of $2.4 million, compared to a negative cash flow in the same period last year, and ended the quarter with $40.2 million in cash and cash equivalents.
Key Highlights
- Q1 2026 net income was $201 thousand, compared to a net loss of $1,165 thousand in Q1 2025.
- PEDMARK product sales increased 72.6% to $15.1 million in Q1 2026 from $8.8 million in Q1 2025.
- Basic and diluted EPS was $0.01 in Q1 2026, up from $(0.04) in Q1 2025.
- Net cash provided by operating activities was $2.4 million in Q1 2026, reversing a $4.3 million use in Q1 2025.
- Cash and cash equivalents rose to $40.2 million as of March 31, 2026, from $36.8 million at year-end 2025.
- Total stockholders' equity increased to $37.7 million as of March 31, 2026, from $35.5 million at year-end 2025.
- General and administrative expenses decreased to $3.2 million in Q1 2026 from $5.9 million in Q1 2025.
Price Impact
More from FENC